Skip to search formSkip to main contentSkip to account menu

ELACYT

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study
Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYT™) is a novel ara-C-5’-elaidic acid ester that… 
2008
2008
Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells
This study evaluated combination drug partners for CP-4055, the C18:1Δ9,trans unsaturated fatty acid ester of cytarabine in HL-60… 
2008
2008
A phase I study with CP-4055 in patients with hematologic malignancies
2532 Background: CP-4055 (ELACYT, cytarabine 5’-elaidic acid ester) is a novel derivative of cytarabine, CP-4055 is independent… 
2007
2007
Proffered papers and posters
The deoxynucleoside analogues cytarabine (Ara-C) and gemcitabine (dFdC) are drugs commonly used in the treatment of cancer. Due… 
2006
2006
A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors.
2067 Background: CP-4055 (ELACYT, ara-C 5'-elaidic acid ester) is a novel cytotoxic agent with broad preclinical antitumor… 
2006
2006
Antiproliferative Activity of ELACYT™ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.
CP-4055 (ara-C-5′-elaidic acid ester; ELACYT™) is the C18:1 Δ9,trans unsaturated fatty acid ester of cytarabine, a deoxycytidine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)